Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead acquired Livdelzi – an oral PPAR delta agonist – as the main asset in its $4.3 billion takeover of CymaBay Therapeutics in February. Prior to that, it was in development for metabolic ...

Our opinions are our own. It can deliver value to Delta devotees, but thanks to its increased annual fee, it's not the no-brainer it used to be.

We now show that NT induces release of extracellular mitochondrial DNA (mtDNA) that could act as "autoimmune" trigger. We further show that serum from young autistic patients contains mtDNA (n ...

"PBC is a rare, slowly progressive autoimmune liver disease and because it is somewhat 'invisible' it may be misunderstood and dismissed by friends, family and even the medical community," said Gail ...

IQIRVO ® (elafibranor) is the first new medicine approved in nearly a decade for the treatment of rare cholestatic liver disease Primary Biliary Cholangitis "PBC is a rare, slowly progressive ...

Delta Corp Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 2,445.55 Crore) operating in Tourism & Hospitality sector. Delta Corp Ltd. key Products/Revenue Segments ...